Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of the candidate herpes zoster vaccine gE/AS01B in adults aged 60 years and older
2010-022248-19Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by GSK. Primary endpoint: Cell-mediated immunity to gE and VZV at Months 48, 60, and 72. Started Dec 2010; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2010-022248-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022248-19.